LRP5 and cancer: CTNNB1 mutations are more commonly associated with “non-proliferative” liver cancers, which include chromosomally stable tumors that retain differentiation markers and hepatocyte-like characteristics.311 Beyond the commonly studied mutations, the Wnt pathway also harbors mutations in other components, such as Fzd, LRP5/6, and TCF/LEF transcription factors.312,313 While Wnt pathway mutations are present in most cancer types, they exhibit significant tissue specificity.